(Total Views: 813)
Posted On: 01/18/2021 11:17:08 PM
Post# of 148903
Ok, I stand corrected. I missed this part of the article:
"Cytodyn disclosed in an investment community conference call that they requested an EUA from FDA for leronlimab for mild to moderate COVID-19 based on data from the Phase 2 CD10 study."
So, the authors just went with that and didn't follow up. Bummer, but great article nonetheless.
"Cytodyn disclosed in an investment community conference call that they requested an EUA from FDA for leronlimab for mild to moderate COVID-19 based on data from the Phase 2 CD10 study."
So, the authors just went with that and didn't follow up. Bummer, but great article nonetheless.
(4)
(0)Scroll down for more posts ▼
